Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / BMY - Evelo Biosciences names former Alnylam MyoKardia CEOs as strategic advisors

BMY - Evelo Biosciences names former Alnylam MyoKardia CEOs as strategic advisors

Bristol-Myers Squibb Company
John Maraganore and Tassos Gianakakos, the former CEOs of, respectively, Alnylam Pharmaceuticals (ALNY) and MyoKardia, are joining Evelo Biosciences (NASDAQ:EVLO) as strategic advisors. Maraganore was Alnylam's founding CEO and just left the company last year, while Gianakakos served as MyoKardia CEO for eight years until the company was acquired by Bristol-Myers Squibb (BMY) in 2020. Evelo (EVLO) is focused on inflammatory diseases. Its latest stasge candidate, EDP1815, is in phase 2 for psoriasis and atopic dermatitis. Shares are up 12% in Friday afternoon trading. Seeking Alpha's Quant Ratings views Evelo (EVLO) as a strong sell.

For further details see:

Evelo Biosciences names former Alnylam, MyoKardia CEOs as strategic advisors
Stock Information
Company Name: Bristol-Myers Squibb Company
Stock Symbol: BMY
Market: NYSE
Website: bms.com
Menu
BMY BMY Quote BMY Short BMY News BMY Articles BMY Message Board
Get BMY Alerts

News, Short Squeeze, Breakout and More Instantly...